GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTPW) » Definitions » Net-Net Working Capital

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Net-Net Working Capital : $0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

60 Degrees Pharmaceuticals's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $0.00.

The industry rank for 60 Degrees Pharmaceuticals's Net-Net Working Capital or its related term are showing as below:

SXTPW's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.125
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

60 Degrees Pharmaceuticals Net-Net Working Capital Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Net-Net Working Capital Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
- - - -

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of 60 Degrees Pharmaceuticals's Net-Net Working Capital

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


60 Degrees Pharmaceuticals's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's Price-to-Net-Net-Working-Capital falls into.



60 Degrees Pharmaceuticals Net-Net Working Capital Calculation

60 Degrees Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(2.142+0.75 * 0.231+0.5 * 0.466-2.986
-9.858--0.072)/0
=N/A

60 Degrees Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(2.895+0.75 * 0.316+0.5 * 0.435-1.254
-9.858--0.075)/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


60 Degrees Pharmaceuticals  (NAS:SXTPW) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


60 Degrees Pharmaceuticals Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Headlines